Clinical Trials Logo
  1. Home
  2. Intractable Pain
  3. NCT00817596

Prometra's Utilization in Mitigating Pain (PUMP) — PUMP  

Intractable Pain Clinical Trial

Official title:
Prometra's Utilization in Mitigating Pain (PUMP)

Clinical Trial Summary

Clinical evaluation of the safety and efficacy of the Prometra Programmable Infusion Pump to accurately supply drug to the intrathecal space for the treatment of chronic pain.

Clinical Trial Description

Chronic conditions of pain and spasticity are and have been major challenges to traditional medical treatment. Chronic pain and spasticity seriously reduce the quality of life and restrict normal daily activities for many people. The first line of defense is normally oral medications. However, a significant number of these patients require additional or alternative therapy due to the side effects of the oral medications or the intractable nature of the condition.

In 1979, Wand et. al. found that small amounts of morphine, when injected into the sub-arachnoid space, had significant affect in reducing pain. Since that time a number of drug products and infusion pumps have been developed to address this condition. The primary drug used for this purpose in preservative-free morphine sulfate solution which is delivered via an implanted intrathecal catheter. The Prometra Intrathecal Pump System is only the second programmable pump to be used in the treatment of chronic pain. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00817596
Study type Interventional
Source Flowonix Medical
Contact
Status Completed
Phase N/A
Start date January 2007
Completion date March 2011
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00996983 - Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer Phase 2
Withdrawn NCT03876158 - Transitioning to a Valve -Gated Intrathecal Drug Delivery System (IDDS) Phase 4
Completed NCT00371865 - Behavioral Treatments for Chronic Pain N/A
Not yet recruiting NCT02522611 - Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain Phase 1/Phase 2
Recruiting NCT04909593 - Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial N/A
Terminated NCT02587130 - Ketamine and Refractory Painful Care in a Palliative Unit Phase 4
Terminated NCT03886753 - Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products
Completed NCT03082261 - Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator N/A
Completed NCT01854229 - Prometra Post-Approval Study N/A
Completed NCT01291901 - NP2 Enkephalin For Treatment of Intractable Cancer Pain Phase 2
Completed NCT01567345 - Intrathecal Morphine Administration Using Implantable Pump With Continuous or Programmable Flow N/A
Terminated NCT00387244 - Efficacy of the Spinal Cord Stimulation System as Salvage Therapy N/A
Recruiting NCT00804154 - Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer Phase 1
Approved for marketing NCT00866164 - Prometra's Utilization in Mitigating Pain II N/A